Key Points
- Director Wayne Pisano bought 5,000 shares on January 8 at an average price of $4.08 (totaling $20,400), increasing his stake to 13,498 shares — a 58.84% rise in his position valued at roughly $55,072.
- Altimmune shares trade around $4.02 with a 52-week range of $2.90 to $7.73 and a market capitalization of about $419.45 million; the 50-day and 200-day simple moving averages are $4.48 and $4.15, respectively.
- Analyst coverage is mixed (six Buys, one Hold, two Sells) giving an average rating of "Hold" and an average price target of $16.60, while institutional investors own roughly 78.05% of the company, with recent notable increases by Two Sigma and Vanguard.
Altimmune, Inc. (NASDAQ:ALT - Get Free Report) Director Wayne Pisano bought 5,000 shares of the firm's stock in a transaction dated Thursday, January 8th. The shares were bought at an average price of $4.08 per share, with a total value of $20,400.00. Following the completion of the transaction, the director directly owned 13,498 shares in the company, valued at approximately $55,071.84. This trade represents a 58.84% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
Altimmune Stock Performance
Shares of NASDAQ:ALT opened at $4.02 on Friday. The firm's 50 day simple moving average is $4.48 and its 200 day simple moving average is $4.15. Altimmune, Inc. has a fifty-two week low of $2.90 and a fifty-two week high of $7.73. The company has a market capitalization of $419.45 million, a price-to-earnings ratio of -3.76 and a beta of 0.04. The company has a debt-to-equity ratio of 0.08, a current ratio of 17.18 and a quick ratio of 17.18.
Altimmune (NASDAQ:ALT - Get Free Report) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.29) by $0.08. Altimmune had a negative net margin of 419,575.00% and a negative return on equity of 54.79%. The firm had revenue of $0.01 million during the quarter, compared to analysts' expectations of $0.00 million. As a group, sell-side analysts forecast that Altimmune, Inc. will post -1.35 earnings per share for the current year.
Analyst Ratings Changes
Several analysts recently commented on the company. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Altimmune in a research note on Monday, December 29th. Citigroup restated a "market outperform" rating on shares of Altimmune in a report on Wednesday, November 12th. HC Wainwright reiterated a "buy" rating and set a $12.00 price objective on shares of Altimmune in a report on Monday, October 20th. Finally, Citizens Jmp decreased their price objective on Altimmune from $15.00 to $14.00 and set a "market outperform" rating for the company in a research report on Friday, November 7th. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $16.60.
Check Out Our Latest Analysis on Altimmune
Institutional Trading of Altimmune
Several hedge funds and other institutional investors have recently modified their holdings of ALT. Two Sigma Investments LP lifted its holdings in shares of Altimmune by 356.6% in the third quarter. Two Sigma Investments LP now owns 1,996,848 shares of the company's stock valued at $7,528,000 after purchasing an additional 1,559,562 shares in the last quarter. Vanguard Group Inc. raised its position in Altimmune by 23.3% in the 3rd quarter. Vanguard Group Inc. now owns 6,373,638 shares of the company's stock valued at $24,029,000 after buying an additional 1,206,514 shares during the last quarter. Federated Hermes Inc. lifted its stake in Altimmune by 387.7% in the 2nd quarter. Federated Hermes Inc. now owns 915,458 shares of the company's stock valued at $3,543,000 after acquiring an additional 727,731 shares in the last quarter. Squarepoint Ops LLC acquired a new position in Altimmune during the 3rd quarter worth approximately $2,204,000. Finally, Bank of America Corp DE boosted its position in Altimmune by 155.2% during the 2nd quarter. Bank of America Corp DE now owns 716,019 shares of the company's stock worth $2,771,000 after acquiring an additional 435,467 shares during the last quarter. Institutional investors and hedge funds own 78.05% of the company's stock.
About Altimmune
(
Get Free Report)
Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune's approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.
Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
